INTERNATIONAL ANXIETY DISORDERS SYMPOSIUM
AMSTERDAM, THE NETHERLANDS
MAY 27-28, 2009
www.adsymposia.org

NEW!

Presentations
• Advances in PTSD
• Advancing drug development in anxiety disorders
• Cognition in anxiety disorders
• Comorbidity of anxiety disorders
• Current trends in OCD treatment
• DSM-V and ICD-10 issues of anxiety disorders
• Visualizing anxiety disorders

Speakers
• Christer Allgulander, Sweden
• David Baldwin, UK
• Wim van den Brink, Netherlands
• Sam Chamberlain, UK
• Damiaan Denys, Netherlands
• Naomi Fineberg, UK
• Christian Grillon, USA
• Dirk Hermans, Belgium
• Eric Hollander, USA
• David Mataix-Cols, UK
• David Nutt, UK
• Miranda Olff, Netherlands
• Michael Otto, USA
• Stefano Pallanti, Italy
• Katharine Phillips, USA
• Predrag Petrovic, Sweden
• Dan Stein, South Africa
• Murray Stein, USA
• Dick Veltman, Netherlands
• Hans-Ulrich Wittchen, Germany
• Joseph Zohar, Israel

International Anxiety Disorders Symposium

ABN-AMRO
Main sponsor
AstraZeneca

https://doi.org/10.1017/S1092852900020150 Published online by Cambridge University Press
Your comments are important to us. This form provides you with the opportunity to express your opinions. Our goal is to make CNS Spectrums your source for practical and clinical neuropsychiatric information. By filling out this Questionnaire, you enable us to incorporate your views about our editorial content in future issues. Please fill out this form in its entirety. Thank you.

Name (please print)

Address

City
State
Zip Code
E-mail
Specialty
Date

Fax: 212-328-0600. Mail: CNS SPECTRUMS, 333 Hudson Street, 7th Floor, New York, NY 10013

1. On a scale of 1 to 5 (1=Poor, 5=Excellent), please indicate your level of interest and/or satisfaction with the editorial content in this issue.

CASE REPORTS
☐ 1  □ 2  □ 3  □ 4  □ 5

ORIGINAL RESEARCH
☐ 1  □ 2  □ 3  □ 4  □ 5

DEPARTMENTS
Trends in Psychopharmacology
☐ 1  □ 2  □ 3  □ 4  □ 5

Clinical Updates in Neuropsychiatry
☐ 1  □ 2  □ 3  □ 4  □ 5

Communique
☐ 1  □ 2  □ 3  □ 4  □ 5

2. Which areas of neuropsychiatry would you like us to cover in the future?

3. Please describe your reading pattern for this issue:
☐ Read cover to cover
☐ Skipped table of contents
☐ Read select items of interest
☐ Skipped text
☐ Did not read

4. On a scale of 1 to 5 (1=Incomplete, 5=Comprehensive), how would you describe the depth of coverage for this issue?

☐ 1  □ 2  □ 3  □ 4  □ 5

5. Any other comments about CNS Spectrums' editorial content, design, or overall usefulness?

6. Please indicate your title:
☐ Neurologist  ☐ Psychiatrist  ☐ Other

*Please select any of the following complimentary educational materials you would like to receive:

CME-ACCREDITED CD-ROMs
☐ Adult ADHD and the Role of Depression
☐ Augmentation Strategies in the Treatment of Major Depressive Disorder
☐ Managing Parkinson's Disease with Continuous Dopaminergic Stimulation
☐ The Treatment of Acute Agitation in Schizophrenia

NON-CME-ACCREDITED CD-ROMs
☐ Long-Term Issues in the Treatment of Sleep Disorders

CLINICAL POCKET REFERENCE GUIDES
☐ The Black Book of Psychotropic Dosing and Monitoring—12th Edition
☐ The Black Book of Alzheimer's Disease—1st Edition
☐ The Black Book of Insomnia—1st Edition
☐ The Black Book of ADHD—1st Edition
☐ The Black Book of Fibromyalgia—1st Edition
ALZHEIMER’S DISEASE
SUMMIT 2009:
From Current Practices to Future Therapies

Date: Saturday, October 17, 2009
Location: Washington, DC
Program Chairs: Pierre N. Tariot, MD and Norman L. Relkin, MD, PhD
Guest Panelists: Russell Katz, MD, of the FDA and Cristina Sampaio, MD, PhD of the EMEA
Guest Speaker: Meryl Comer, member of the Alzheimer’s Study Group

For more information, please call 212-328-0800 ext. 266 or visit www.alzsummit.com
For registration updates, please e-mail ks@mblcommunications.com
Defining the role of alpha-2A receptors within ADHD

New preclinical science suggests that stimulation of alpha-2A receptors located throughout the prefrontal cortex (PFC) strengthens executive function including working memory, which is thought to play an important role within ADHD. 1-3

Our current understanding of ADHD treatment includes, in part, increasing levels of norepinephrine that act at the alpha-2A receptor. 1 Directly engaging these receptors is thought to exert a positive effect on cognitive functioning, such as behavioral inhibition and impulse control. 1,4

As we continue to learn more about ADHD, we must consider the emerging role of the alpha-2A receptor—it's big.